Ionis Pharmaceuticals, headquartered in Carlsbad, California, develops drugs using antisense technology and has five marketed medicines, including SPINRAZA and QALSODY, with a pipeline focused on neurology and cardiology. The company employs 927 people and has nine medicines in Phase III development.
Joseph Baroldi sold 3,928 shares of IONS on 16 April at $28.40 per share, worth a total of $112K. They now own 31,926 IONS shares, or a 11% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
